What question did this study set out to answer?

This research aims to explore the impact of GPVI deficiency on clot formation under different glucose conditions.

March 25, 2026Open Access

GPVI deficiency reduces clot size and murine thrombosis in normoglycaemic but not hyperglycemic conditions

Key Result

GPVI deficiency reduces clot size and thrombosis under normoglycemic conditions only, with no effect observed during hyperglycemia.

Key Points

This research aims to explore the impact of GPVI deficiency on clot formation under different glucose conditions.
Analyzed the effects of GPVI deficiency in murine models
Compared clot size in normoglycemic and hyperglycemic states
Examined thrombosis development in varying glucose environments
Clot size was significantly reduced in normoglycemic conditions with GPVI deficiency
No significant reduction in clot size was observed in hyperglycemic conditions
Indicates a potential specific role for GPVI in clot formation when glucose levels are normal.

Structured PICO

Does GPVI deficiency reduce clot size and thrombosis in murine models under normoglycaemic versus hyperglycemic conditions?

Population

Murine models under normoglycaemic and hyperglycemic conditions

Intervention

GPVI deficiency

Outcome

Clot size and thrombosissurrogate

GPVI mediates thrombosis exclusively under normoglycaemic conditions in mice, indicating that hyperglycemia alters the mechanisms of clot formation.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Our data suggest that clot formation is affected differentially by absence of GPVI in normo- vs hyperglycemia, supporting a role for GPVI in thrombosis under normoglycaemic conditions only.